Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Ophthalmology

Long-Term Monitoring & Building Your Care Team

At a Glance

Long-term follow-up helps protect vision in intermediate uveitis, even when the eye feels quiet. Monitoring may include vision and eye-pressure checks, dilated exams, OCT scans, and occasional angiography, with specialists and support added when needed.

Because intermediate uveitis can be “insidious”—meaning it can cause damage quietly without pain—protecting your vision may require long-term follow-up and a consistent monitoring schedule [1][2]. The frequency of these visits is highly individualized: active disease or medication changes may require visits every few weeks, while patients who enter prolonged remission can be seen less frequently.

Building Your Care Team

Depending on your diagnosis, you may need a “multidisciplinary” team of specialists working together, though many patients can be managed by an ophthalmologist alone [3][4].

  • Uveitis or Retina Specialist: This is the lead doctor for your eye care. They monitor the level of inflammation, perform specialized imaging, and manage eye-specific treatments like injections or implants [2].
  • Rheumatologist: If you require “steroid-sparing” medications (like methotrexate or biologics) to control your inflammation, or if you have a systemic disease like sarcoidosis, a rheumatologist often manages these systemic drugs and monitors your overall health [3][2].
  • Neurologist: A neurologist is not routinely required for everyone, but may be consulted based on specific neurological symptoms, imaging, or a specific risk assessment for conditions like Multiple Sclerosis [5][6].
  • Pediatric Ophthalmologist: For children, these specialists are essential to monitor how inflammation affects visual development and to prevent “lazy eye” (amblyopia) [2][3].

Your Surveillance Schedule

Once your inflammation is under control (remission), your appointments will be spaced out based on your specific risks. A typical monitoring visit includes several core components:

  1. Visual Acuity and IOP Check: Measuring how well you see and checking your eye pressure (IOP) at every visit is crucial, especially if you are using steroids [7][8].
  2. Slit-Lamp and Dilated Exam: Your doctor will look for inflammatory cells in the vitreous and check the health of your lens and retina [7][9].
  3. Macular OCT: This high-definition scan is used to check for Cystoid Macular Edema (CME), which can recur even when the eye looks “quiet” during a regular exam [10][11].
  4. Wide-Field Fluorescein Angiography (FA): Occasionally, your doctor may use this dye test to check for hidden inflammation in the blood vessels at the very edge of the retina [12][13].

In children, specialized guidance sometimes suggests exams every 8 to 12 weeks once the disease is stable as one possible framework, though your doctor will personalize this based on your child’s specific history [14].

Managing the Psychological Toll

Living with a chronic condition and the constant “waiting for the next scan” can lead to a phenomenon known as scan anxiety [15].

  • Acknowledge the Stress: It is normal to feel anxious about vision loss or frustrated by treatment side effects [16]. Evidence shows that emotional health is strongly associated with your overall quality of life while managing uveitis [15][17].
  • Medication Adherence: While missed doses can contribute to poor disease control, it is also true that treatment can fail despite perfect adherence because the disease is resistant or the medication is not the right fit [18]. Using pill organizers or phone reminders can help. If you find it hard to manage your medications, talk to your care team without judgment—they can often adjust the plan.
  • Support Systems: Patients who feel they have strong social support often report a better quality of life [15][19]. Consider finding a uveitis support group or speaking with a counselor who specializes in chronic illness.

Tips for Long-Term Success

  • Keep a “Vision Journal”: Note any fluctuations in your vision or side effects from new medications to discuss at your next visit [16].
  • Childhood Transitions: As children with intermediate uveitis grow into adulthood, a structured “hand-off” from pediatric to adult specialists is vital to prevent gaps in care that could lead to flares [20].

Common questions in this guide

How often are follow-up visits needed for intermediate uveitis?
The schedule depends on whether the inflammation is active, which medicines you use, and how long you have been in remission. Active disease or medication changes may require visits every few weeks, while stable remission may allow more time between visits. For a child with stable disease, exams every 8 to 12 weeks may be one starting framework, but the ophthalmologist should personalize it.
What happens at a monitoring visit for intermediate uveitis?
Your team may measure visual acuity and eye pressure, examine the eye with a slit lamp and dilation, and use OCT to look for cystoid macular edema. Fluorescein angiography may be used from time to time to find inflammation in peripheral retinal blood vessels that is not obvious on a routine exam. The exact tests and frequency depend on your symptoms, treatment, and disease history.
Which specialists might be part of my intermediate uveitis care team?
An ophthalmologist with uveitis or retina expertise may lead your eye care. A rheumatologist may help manage methotrexate, biologics, or other body-wide medicines, while a neurologist may be involved for neurological symptoms or a multiple sclerosis risk assessment. Children may also need a pediatric ophthalmologist to protect visual development and reduce the risk of amblyopia, sometimes called lazy eye.
Who checks my blood work if I take a biologic or immunosuppressant for uveitis?
The clinician prescribing the systemic medicine should explain which blood tests are needed and who reviews them; this may be a rheumatologist, ophthalmologist, or another member of your team. Ask your care coordinator to confirm the testing schedule, how results will be shared, and what to do if a result is abnormal.
How can I manage scan anxiety and stay on track with intermediate uveitis treatment?
Feeling anxious before scans or frustrated by side effects is common when living with a chronic eye condition. Phone reminders, a pill organizer, and a vision journal can support treatment routines, while a uveitis support group or counselor can help with stress. Tell your care team if a plan is hard to follow or if treatment is not working, because missed doses are not the only reason treatment can fail.
What should I do if I have a sudden flare outside office hours?
Ask your care team in advance for an after-hours phone number and clear instructions for sudden vision changes or other concerns. Follow that plan rather than waiting for the next routine visit, and seek urgent medical care when your clinicians advise it.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Intermediate uveitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Who is the 'lead' coordinator of my care team if I need systemic medications?
  2. 2.How often will we perform OCT scans and fluorescein angiography (FA) once my eyes reach a 'quiet' state?
  3. 3.If we start a biologic or immunosuppressant, who will be responsible for my regular blood work and safety monitoring?
  4. 4.What is the 'emergency protocol' for reaching a member of my care team after hours or on weekends if I have a sudden flare?

References

References (20)
  1. 1

    Remission of Intermediate Uveitis: Incidence and Predictive Factors.

    Kempen JH, Gewaily DY, Newcomb CW, et al.

    American journal of ophthalmology 2016; (164()):110-7.e2.

    PMID: 26772874
  2. 2

    Clinical Course and Treatment Paradigms for JIA-related Uveitis and Pars Planitis Uveitis Using Precise Ocular Investigational Methods.

    Papasavvas I, Gehrig B, Herbort CP

    Klinische Monatsblatter fur Augenheilkunde 2021; (238(4)):458-468 doi:10.1055/a-1354-6452.

    PMID: 33607692
  3. 3

    An Overview of Pediatric Uveitis.

    Tuğal-Tutkun İ

    Turkish archives of pediatrics 2023; (58(4)):363-370 doi:10.5152/TurkArchPediatr.2023.23086.

    PMID: 37357450
  4. 4

    Uveitis in Adults: A Review.

    Maghsoudlou P, Epps SJ, Guly CM, Dick AD

    JAMA 2025; (334(5)):419-434 doi:10.1001/jama.2025.4358.

    PMID: 40434762
  5. 5

    Relevance of Brain MRI in Patients with Uveitis: Retrospective Cohort on 402 Patients.

    Chirpaz NM, Kerever SMP, Gavoille AM, et al.

    Ocular immunology and inflammation 2022; (30(5)):1109-1115 doi:10.1080/09273948.2020.1870145.

    PMID: 33826481
  6. 6

    Clinical characteristics of intermediate uveitis in adults according to criteria of the SUN working group.

    Yargi-Ozkocak B, Altan C, Kemer-Atik B, Basarir B

    International ophthalmology 2023; (43(10)):3681-3693 doi:10.1007/s10792-023-02778-z.

    PMID: 37395903
  7. 7

    Clinical Features, Complications, and Treatment Outcomes of Pediatric Pars Planitis Cases in a Tertiary Referral Center.

    Gülmez Sevim D, Sener H, Ozer F, et al.

    Ocular immunology and inflammation 2025; (33(6)):885-891 doi:10.1080/09273948.2025.2462193.

    PMID: 39946199
  8. 8

    Long-Term Outcomes of Pediatric Idiopathic Intermediate Uveitis.

    AlBloushi AF, Solebo AL, Gokhale E, et al.

    American journal of ophthalmology 2022; (237()):41-48 doi:10.1016/j.ajo.2021.11.003.

    PMID: 34780797
  9. 9

    Uveitis Profile in Children and Its Impact on Vision at Queen Rania Children's Hospital.

    Otoum MM, Al Adwan NM, Haddad HK, et al.

    Cureus 2024; (16(4)):e59136 doi:10.7759/cureus.59136.

    PMID: 38803751
  10. 10

    Spectral-domain optical coherence tomography findings of the macula in 500 consecutive patients with uveitis.

    Grajewski RS, Boelke AC, Adler W, et al.

    Eye (London, England) 2016; (30(11)):1415-1423 doi:10.1038/eye.2016.133.

    PMID: 27391933
  11. 11

    Discrepancy in Fluorescein Angiography and Optical Coherence Tomography Findings of Macular Edema in Intermediate Uveitis.

    Kim BH, Shin JY, Yu HG

    Ocular immunology and inflammation 2016; (24(6)):653-659 doi:10.3109/09273948.2015.1063668.

    PMID: 26645484
  12. 12

    Ultra-Widefield Fluorescein Angiography in Intermediate Uveitis.

    Laovirojjanakul W, Acharya N, Gonzales JA

    Ocular immunology and inflammation 2019; (27(3)):356-361 doi:10.1080/09273948.2017.1371764.

    PMID: 29040047
  13. 13

    The Detection of Occult Retinal Vasculitis on Fluorescein Angiography in Pediatric Uveitis.

    Abraham A, Saboo US, Ducca BL, et al.

    Ophthalmology. Retina 2020; (4(2)):198-203 doi:10.1016/j.oret.2019.09.007.

    PMID: 31708487
  14. 14

    Pediatric uveitis: A comprehensive review.

    Maleki A, Anesi SD, Look-Why S, et al.

    Survey of ophthalmology 2022; (67(2)):510-529 doi:10.1016/j.survophthal.2021.06.006.

    PMID: 34181974
  15. 15

    Predictors of health-related quality of life in Chinese patients receiving treatment for neovascular age-related macular degeneration: a prospective longitudinal study.

    Bian W, Wan J, Tan M, et al.

    BMC ophthalmology 2020; (20(1)):291 doi:10.1186/s12886-020-01561-3.

    PMID: 32677913
  16. 16

    Outcomes in patients with chronic uveitis: which factors matter to patients? A qualitative study.

    Stolk-Vos AC, Kasigar H, Nijmeijer KJ, et al.

    BMC ophthalmology 2020; (20(1)):125 doi:10.1186/s12886-020-01388-y.

    PMID: 32228570
  17. 17

    Development and Psychometric Properties of the Chronic Uveitis-Specific Quality of Life Instrument for Patients with Chronic Uveitis.

    Linghu W, Niu M, Sun N, et al.

    Ocular immunology and inflammation 2024; (32(2)):194-202 doi:10.1080/09273948.2022.2162926.

    PMID: 36638326
  18. 18

    Treatment adherence in chronic uveitis: What does the MARS-5 tell us?

    Caglayan M, Ekinci DY, Dertsiz Kozan B

    BMC ophthalmology 2026; (26(1)).

    PMID: 41772494
  19. 19

    Impact of COVID-19 Confinement on Quality of Life of Patients with Age-Related Macular Degeneration: A Two-Wave Panel Study.

    Sanabria MR, Calles-Monar PS, Alonso-Tarancón AM, et al.

    Journal of clinical medicine 2023; (12(6)) doi:10.3390/jcm12062394.

    PMID: 36983394
  20. 20

    Characteristics of JIA-associated uveitis at the age of transition.

    Raymond A, Combier A, Hecquet S, et al.

    Pediatric rheumatology online journal 2026; (24(1)).

    PMID: 42152096

This page explains long-term monitoring and care-team roles for intermediate uveitis for informational purposes only and does not constitute medical advice. Your ophthalmologist or uveitis specialist should tailor the follow-up schedule, tests, and treatment to your needs.